Gain Therapeutics, Inc.
GANX
$1.72
-$0.11-6.01%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -22.80% | 18.36% | |||
| Gross Profit | 22.80% | -18.36% | |||
| SG&A Expenses | -1.82% | 21.23% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -12.56% | 19.74% | |||
| Operating Income | 12.56% | -19.74% | |||
| Income Before Tax | 15.74% | -21.45% | |||
| Income Tax Expenses | -43.15% | 161.20% | |||
| Earnings from Continuing Operations | 16.64% | -23.60% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 16.64% | -23.60% | |||
| EBIT | 12.56% | -19.74% | |||
| EBITDA | 12.67% | -19.94% | |||
| EPS Basic | 17.92% | -10.67% | |||
| Normalized Basic EPS | 17.06% | -8.81% | |||
| EPS Diluted | 17.92% | -10.67% | |||
| Normalized Diluted EPS | 17.06% | -8.81% | |||
| Average Basic Shares Outstanding | 1.54% | 11.66% | |||
| Average Diluted Shares Outstanding | 1.54% | 11.66% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||